ondansetron has been researched along with Anankastic Personality in 15 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| " granisetron in patients with treatment-resistant obsessive-compulsive disorder." | 9.30 | Comparing the efficacy of ondansetron and granisetron augmentation in treatment-resistant obsessive-compulsive disorder: a randomized double-blind placebo-controlled study. ( Abdolrazaghnejad, A; Aghakarim Alamdar, M; Ebrahimi-Monfared, M; Massoudifar, A; Mohammadbeigi, A; Saber, R; Sharafkhah, M, 2019) |
| "The aim of this study was to evaluate low-dose ondansetron as an augmentation strategy in patients with obsessive-compulsive disorder (OCD) who do not adequately respond to serotonin reuptake inhibits (SRIs)." | 9.19 | Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: improvement with treatment and worsening following discontinuation. ( Antonini, S; Bernardi, S; Hollander, E; Pallanti, S; Singh, N, 2014) |
| "The aim of this study was to investigate the efficacy and safety of ondansetron as an augmentative agent to fluvoxamine in the treatment of patients with obsessive-compulsive disorder (OCD)." | 9.19 | Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder. ( Akhondzadeh, S; Fallah, J; Heidari, M; Hosseini, SM; Maleki, H; Tabrizi, M; Taghvaei, R; Zarei, M, 2014) |
| "To assess the efficacy and tolerability of ondansetron in combination with selective serotonin reuptake inhibitors (SSRIs) in patients with obsessive-compulsive disorder (OCD)." | 9.14 | A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder. ( Feizy, F; Malayeri, A; Motlagh, I; Sayyah, M; Siahpoosh, A; Soltani, F, 2010) |
| " Initially, for his leukemia, he was treated with chemotherapy, which resulted in severe nausea and vomiting for which he was given ondansetron." | 7.74 | The successful use of ondansetron in a boy with both leukemia and Tourette syndrome. ( Gulisano, M; Marino, S; Rizzo, R; Robertson, MM, 2008) |
| " The drug was initiated at a dosage of 0." | 6.74 | Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study. ( Antonini, S; Bernardi, S; Hollander, E; Pallanti, S; Singh, N, 2009) |
| "Pretreatment with ondansetron did not affect any of the self-rated behavioral symptoms." | 6.69 | Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results. ( Broocks, A; Canter, S; Grady, TA; Hill, JL; L'Heureux, F; Murphy, DL; Pigott, TA, 1998) |
| "Ondansetron is an experimental alternative for such patients." | 5.42 | Ondansetron augmentation of serotonin reuptake inhibitors as a treatment strategy in obsessive-compulsive disorder. ( Andrade, C, 2015) |
| " granisetron in patients with treatment-resistant obsessive-compulsive disorder." | 5.30 | Comparing the efficacy of ondansetron and granisetron augmentation in treatment-resistant obsessive-compulsive disorder: a randomized double-blind placebo-controlled study. ( Abdolrazaghnejad, A; Aghakarim Alamdar, M; Ebrahimi-Monfared, M; Massoudifar, A; Mohammadbeigi, A; Saber, R; Sharafkhah, M, 2019) |
| "The aim of this study was to evaluate low-dose ondansetron as an augmentation strategy in patients with obsessive-compulsive disorder (OCD) who do not adequately respond to serotonin reuptake inhibits (SRIs)." | 5.19 | Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: improvement with treatment and worsening following discontinuation. ( Antonini, S; Bernardi, S; Hollander, E; Pallanti, S; Singh, N, 2014) |
| "The aim of this study was to investigate the efficacy and safety of ondansetron as an augmentative agent to fluvoxamine in the treatment of patients with obsessive-compulsive disorder (OCD)." | 5.19 | Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder. ( Akhondzadeh, S; Fallah, J; Heidari, M; Hosseini, SM; Maleki, H; Tabrizi, M; Taghvaei, R; Zarei, M, 2014) |
| "To assess the efficacy and tolerability of ondansetron in combination with selective serotonin reuptake inhibitors (SSRIs) in patients with obsessive-compulsive disorder (OCD)." | 5.14 | A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder. ( Feizy, F; Malayeri, A; Motlagh, I; Sayyah, M; Siahpoosh, A; Soltani, F, 2010) |
| " Initially, for his leukemia, he was treated with chemotherapy, which resulted in severe nausea and vomiting for which he was given ondansetron." | 3.74 | The successful use of ondansetron in a boy with both leukemia and Tourette syndrome. ( Gulisano, M; Marino, S; Rizzo, R; Robertson, MM, 2008) |
| "Memantine was found to be most effective augmentation agent for SRIs in OCD, followed by lamotrigine, ondansetron and granisetron with moderate certainty of evidence." | 3.01 | Pharmacological augmentation of serotonin reuptake inhibitors in patients with obsessive-compulsive disorder: A network meta-analysis. ( Maiti, R; Mishra, A; Mishra, BR; Srinivasan, A, 2023) |
| " The drug was initiated at a dosage of 0." | 2.74 | Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study. ( Antonini, S; Bernardi, S; Hollander, E; Pallanti, S; Singh, N, 2009) |
| "Pretreatment with ondansetron did not affect any of the self-rated behavioral symptoms." | 2.69 | Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results. ( Broocks, A; Canter, S; Grady, TA; Hill, JL; L'Heureux, F; Murphy, DL; Pigott, TA, 1998) |
| "Ondansetron treatment was associated with a significant decrease in the severity of tics." | 2.69 | Ondansetron treatment in patients with Tourette's syndrome. ( Cohen, DJ; Laor, N; Toren, P; Weizman, A; Wolmer, L, 1999) |
| "Ondansetron is an experimental alternative for such patients." | 1.42 | Ondansetron augmentation of serotonin reuptake inhibitors as a treatment strategy in obsessive-compulsive disorder. ( Andrade, C, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 3 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Suhas, S | 1 |
| Malo, PK | 1 |
| Kumar, V | 1 |
| Issac, TG | 1 |
| Chithra, NK | 1 |
| Bhaskarapillai, B | 1 |
| Reddy, YCJ | 2 |
| Rao, NP | 1 |
| Maiti, R | 1 |
| Mishra, A | 1 |
| Srinivasan, A | 1 |
| Mishra, BR | 1 |
| Yadav, S | 1 |
| Takács, A | 1 |
| Pantelis, C | 1 |
| Thomas, N | 1 |
| Kalyani, BG | 1 |
| Hegde, A | 1 |
| Arumugham, SS | 1 |
| Narayanaswamy, JC | 1 |
| Math, SB | 1 |
| M Koran, L | 1 |
| Aboujaoude, E | 1 |
| Sharafkhah, M | 1 |
| Aghakarim Alamdar, M | 1 |
| Massoudifar, A | 1 |
| Abdolrazaghnejad, A | 1 |
| Ebrahimi-Monfared, M | 1 |
| Saber, R | 1 |
| Mohammadbeigi, A | 1 |
| Pallanti, S | 2 |
| Bernardi, S | 2 |
| Antonini, S | 2 |
| Singh, N | 2 |
| Hollander, E | 2 |
| Heidari, M | 1 |
| Zarei, M | 1 |
| Hosseini, SM | 1 |
| Taghvaei, R | 1 |
| Maleki, H | 1 |
| Tabrizi, M | 1 |
| Fallah, J | 1 |
| Akhondzadeh, S | 1 |
| Andrade, C | 1 |
| Soltani, F | 1 |
| Sayyah, M | 1 |
| Feizy, F | 1 |
| Malayeri, A | 1 |
| Siahpoosh, A | 1 |
| Motlagh, I | 1 |
| Hewlett, WA | 1 |
| Schmid, SP | 1 |
| Salomon, RM | 1 |
| Rizzo, R | 1 |
| Marino, S | 1 |
| Gulisano, M | 1 |
| Robertson, MM | 1 |
| Broocks, A | 1 |
| Pigott, TA | 1 |
| Hill, JL | 1 |
| Canter, S | 1 |
| Grady, TA | 1 |
| L'Heureux, F | 1 |
| Murphy, DL | 1 |
| Toren, P | 1 |
| Laor, N | 1 |
| Cohen, DJ | 1 |
| Wolmer, L | 1 |
| Weizman, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Ondansetron Augmentation in Treatment Resistant Obsessive Compulsive Disorder: A Preliminary Single-Blind Prospective Study[NCT00796497] | Phase 4 | 14 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for ondansetron and Anankastic Personality
| Article | Year |
|---|---|
Treatment strategies for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: A network meta-analysis of randomised controlled trials.
Topics: Adult; Aripiprazole; Child; Chronic Disease; Humans; Network Meta-Analysis; Obsessive-Compulsive Dis | 2023 |
Pharmacological augmentation of serotonin reuptake inhibitors in patients with obsessive-compulsive disorder: A network meta-analysis.
Topics: Bayes Theorem; Drug Therapy, Combination; Granisetron; Humans; Lamotrigine; Memantine; Network Meta- | 2023 |
Promising Treatments for Obsessive-Compulsive Disorder: A Call for Additional Research.
Topics: Caffeine; Cognitive Behavioral Therapy; Combined Modality Therapy; Humans; Ketamine; Memantine; Obse | 2018 |
8 trials available for ondansetron and Anankastic Personality
| Article | Year |
|---|---|
Comparing the efficacy of ondansetron and granisetron augmentation in treatment-resistant obsessive-compulsive disorder: a randomized double-blind placebo-controlled study.
Topics: Double-Blind Method; Granisetron; Obsessive-Compulsive Disorder; Ondansetron; Serotonin Antagonists | 2019 |
Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: improvement with treatment and worsening following discontinuation.
Topics: Adult; Aged; Anti-Anxiety Agents; Drug Synergism; Drug Therapy, Combination; Female; Humans; Male; M | 2014 |
Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder.
Topics: Adolescent; Adult; Double-Blind Method; Drug Therapy, Combination; Female; Fluvoxamine; Humans; Male | 2014 |
Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study.
Topics: Adolescent; Adult; Antipsychotic Agents; Drug Resistance; Drug Therapy, Combination; Female; Humans; | 2009 |
A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder.
Topics: Adult; Double-Blind Method; Drug Therapy, Combination; Female; Fluoxetine; Humans; Interview, Psycho | 2010 |
Pilot trial of ondansetron in the treatment of 8 patients with obsessive-compulsive disorder.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Ob | 2003 |
Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results.
Topics: Adult; Analysis of Variance; Behavioral Symptoms; Double-Blind Method; Drug Interactions; Female; Hu | 1998 |
Ondansetron treatment in patients with Tourette's syndrome.
Topics: Adolescent; Adult; Female; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Ondansetron; Pi | 1999 |
4 other studies available for ondansetron and Anankastic Personality
| Article | Year |
|---|---|
Ondansetron augmentation for the management of obsessive-compulsive disorder in a patient with treatment-resistant schizophrenia.
Topics: Humans; Obsessive-Compulsive Disorder; Ondansetron; Schizophrenia; Selective Serotonin Reuptake Inhi | 2021 |
Is Ondansetron Augmentation Effective in Obsessive-Compulsive Disorder?
Topics: Drug Therapy, Combination; Humans; Obsessive-Compulsive Disorder; Ondansetron; Outcome Assessment, H | 2017 |
Ondansetron augmentation of serotonin reuptake inhibitors as a treatment strategy in obsessive-compulsive disorder.
Topics: Clinical Trials as Topic; Drug Synergism; Drug Therapy, Combination; Humans; Obsessive-Compulsive Di | 2015 |
The successful use of ondansetron in a boy with both leukemia and Tourette syndrome.
Topics: Anti-Dyskinesia Agents; Antiemetics; Antineoplastic Agents; Biperiden; Brain; Child; Dose-Response R | 2008 |